Literature DB >> 15357785

Functional consequences of haemophilia in adults: the development of the Haemophilia Activities List.

F R van Genderen1, N L U van Meeteren, J G van der Bom, L Heijnen, P de Kleijn, H M van den Berg, P J M Helders.   

Abstract

Several instruments can be used to evaluate the functional status of patients with haemophilia, but none of these instruments is specific for haemophilia. We developed a haemophilia-specific self-assessment questionnaire to evaluate and monitor a patient's perceived functional health status: the Haemophilia Activities List (HAL). In three separate but interlinked substudies, the questionnaire was constructed and tested for face, expert, and convergent validity, as well as internal consistency and patient-evaluated relevance. Items for the questionnaire were collected by interviewing 162 patients, using the McMaster-Toronto Arthritis Patient Preference Disability Questionnaire (MACTAR). The items were combined to generate the first version of the questionnaire [HAL(1)]. This version was evaluated and commented on by two focus groups (patients and caregivers), and then the questionnaire was adapted on the basis of these comments, forming the final version, HAL(2). This version was then validated in a pilot study with 50 consecutive patients using the Dutch Arthritis Impact Measurements Scales 2 (Dutch-AIMS2) and the Impact on Participation and Autonomy (IPA) questionnaires. The HAL(2) showed good convergent validity (Pearson correlation 0.80-0.91; P < 0.01), and the internal consistency was good for six of the eight domains (Cronbach's alpha 0.83-0.95). Patients considered the content of the HAL to be more relevant to their situation than the content of the other questionnaires (P < 0.01). Three major factors (upper extremity function, lower extremity function, key activities/major problem activities) were identified by factor analysis. The questionnaire seems to be a useful tool to identify problematic activities as part of the functional health status of patients with haemophilia. The construct validity, test-retest reliability, and responsiveness of the HAL will be established in the future.

Entities:  

Mesh:

Year:  2004        PMID: 15357785     DOI: 10.1111/j.1365-2516.2004.01016.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  15 in total

1.  A Combined Ultrasonographic and Conventional Radiographic Assessment of Hemophilic Arthropathy.

Authors:  So-Won Chung; Young-Jae Seo; Chur Woo You; Tong-Jin Chun; Kang-Jae Jung; Jae-Hyung Kim
Journal:  Indian J Hematol Blood Transfus       Date:  2016-08-18       Impact factor: 0.900

2.  Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s.

Authors:  Kathelijn Fischer; Katarina Steen Carlsson; Pia Petrini; Margareta Holmström; Rolf Ljung; H Marijke van den Berg; Erik Berntorp
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

3.  Content comparison of haemophilia specific patient-rated outcome measures with the international classification of functioning, disability and health (ICF, ICF-CY).

Authors:  Silvia Riva; Monika Bullinger; Edda Amann; Sylvia von Mackensen
Journal:  Health Qual Life Outcomes       Date:  2010-11-25       Impact factor: 3.186

4.  Reliability of patient-reported outcome instruments in US adults with hemophilia: the Pain, Functional Impairment and Quality of life (P-FiQ) study.

Authors:  Christine L Kempton; Michael Wang; Michael Recht; Anne Neff; Amy D Shapiro; Amit Soni; Roshni Kulkarni; Tyler W Buckner; Katharine Batt; Neeraj N Iyer; David L Cooper
Journal:  Patient Prefer Adherence       Date:  2017-09-19       Impact factor: 2.711

5.  Internal consistency and item-total correlation of patient-reported outcome instruments and hemophilia joint health score v2.1 in US adult people with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study.

Authors:  Michael Wang; Katharine Batt; Craig Kessler; Anne Neff; Neeraj N Iyer; David L Cooper; Christine L Kempton
Journal:  Patient Prefer Adherence       Date:  2017-10-25       Impact factor: 2.711

6.  Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study.

Authors:  Karin P M van Galen; Piet de Kleijn; Wouter Foppen; Jeroen Eikenboom; Karina Meijer; Roger E G Schutgens; Kathelijn Fischer; Marjon H Cnossen; Joke de Meris; Karin Fijnvandraat; Johanna G van der Bom; Britta A P Laros-van Gorkom; Frank W G Leebeek; Eveline P Mauser-Bunschoten
Journal:  Haematologica       Date:  2017-06-01       Impact factor: 9.941

7.  Sports participation and physical activity in adult Dutch and Swedish patients with severe haemophilia: A comparison between intermediate- and high-dose prophylaxis.

Authors:  Olav Versloot; Erik Berntorp; Pia Petrini; Rolf Ljung; Jan Astermark; Margareta Holmström; Piet de Kleijn; Kathelijn Fischer
Journal:  Haemophilia       Date:  2019-01-28       Impact factor: 4.287

8.  Professional functioning of young adults with congenital coagulation disorders in the Netherlands.

Authors:  Perrine F Limperg; Heleen Maurice-Stam; Lotte Haverman; Michiel Coppens; Marieke J H A Kruip; Jeroen Eikenboom; Martha A Grootenhuis; Marjolein Peters
Journal:  Haemophilia       Date:  2019-03-12       Impact factor: 4.287

9.  Construct validity of patient-reported outcome instruments in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study.

Authors:  Katharine Batt; Michael Recht; David L Cooper; Neeraj N Iyer; Christine L Kempton
Journal:  Patient Prefer Adherence       Date:  2017-08-09       Impact factor: 2.711

10.  Known-group validity of patient-reported outcome instruments and hemophilia joint health score v2.1 in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study.

Authors:  Tyler W Buckner; Michael Wang; David L Cooper; Neeraj N Iyer; Christine L Kempton
Journal:  Patient Prefer Adherence       Date:  2017-10-11       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.